Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review.

J Pers Med · 2020 · PMC7563856 · PMID 32759686

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

High bFGF and ICAM-1 levels also showed a trend toward a higher risk of death ( p = 0.06 both).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.